Healthcare -
Biotechnology - NASDAQ - US
$ 0.3462
-5.8 %
$ 8.73 M
Market Cap
-0.32
P/E
1. INTRINSIC VALUE
Balance Sheet
Sensei Biotherapeutics, Inc.
| Current Assets | 41.9 M |
| Cash & Short-Term Investments | 41.3 M |
| Receivables | 0 |
| Other Current Assets | 594 K |
| Non-Current Assets | 3.43 M |
| Long-Term Investments | 0 |
| PP&E | 3.38 M |
| Other Non-Current Assets | 48 K |
| Current Liabilities | 5.45 M |
| Accounts Payable | 0 |
| Short-Term Debt | 2.32 M |
| Other Current Liabilities | 3.13 M |
| Non-Current Liabilities | 1.53 M |
| Long-Term Debt | 1.53 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Sensei Biotherapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 32.6 M |
| Operating Income | -32.6 M |
| Other Expenses | -2.46 M |
| Net Income | -30.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sensei Biotherapeutics, Inc.
| Net Income | -30.2 M |
| Depreciation & Amortization | 1.32 M |
| Capital Expenditures | -146 K |
| Stock-Based Compensation | 3.14 M |
| Change in Working Capital | -489 K |
| Others | 1.48 M |
| Free Cash Flow | -24.8 M |
Wall Street Analysts Price Targets
Sensei Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for SNSE of $5 , with forecasts ranging from
a
low of
$5 to a high of $5 .
SNSE Lowest Price Target
Wall Street Target
5 USD
1344.25%
SNSE Average Price Target
Wall Street Target
5 USD
1344.25%
SNSE Highest Price Target
Wall Street Target
5 USD
1344.25%
4. DIVIDEND
ANALYSIS
SNSE does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sensei Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET.
globenewswire.com
- 1 month ago
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population -
globenewswire.com
- 1 month ago
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing –
globenewswire.com
- 1 month ago
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock
Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 2 months ago
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET.
globenewswire.com
- 2 months ago
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. “2024 was a noteworthy year for Sensei and our pioneering lead program, solnerstotug.
globenewswire.com
- 3 months ago
Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi's 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.
globenewswire.com
- 5 months ago
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. “The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors.
globenewswire.com
- 5 months ago
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences.
globenewswire.com
- 6 months ago
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD.
globenewswire.com
- 7 months ago
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024:
globenewswire.com
- 7 months ago
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. “Collectively, the clinical data presented on SNS-101 over the past six months demonstrated early signs of clinical activity in a patient population generally resistant to immunotherapy, a well-tolerated safety profile, and the avoidance of a pharmacokinetic sink that hindered first-generation approaches to targeting VISTA,” said John Celebi, President and Chief Executive Officer.
globenewswire.com
- 8 months ago
8. Profile
Summary
Sensei Biotherapeutics, Inc. SNSE
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 8.73 M
Dividend Yield
0.00%
Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Contact
451 D Street, Rockville, MD, 02210
https://www.senseibio.com
IPO
Date
Feb. 4, 2021
Employees
14
Officers
Mr. John K. Celebi M.B.A.
President, Chief Executive Officer & Director
Mr. Christopher W. Gerry J.D.
Senior Vice President, General Counsel & Secretary
Dr. Edward Van der Horst Ph.D.
Chief Scientific Officer
Dr. Aaron Weitzman FACP, M.D., Ph.D.
Chief Medical Officer
Ms. Stephanie Krebs M.B.A., M.S.
Chief Business Officer
Mr. Josiah Craver
Senior Vice President of Finance, Principal Financial Officer & Principal Accounting Officer
Ms. Lora Pike
Vice President of Investor Relations & Communications